Global Duchenne Muscular Dystrophy Market Study 2016-2026, by Segment (Deflazacort, Prednisone), by Market (Male, Female), by Company (PTC Therapeutics, Sarepta Therapeutics)

ReportPage
Report ID
82695
Published Date
13-Nov
No of Report Page
51
Report Category
Medical Devices
Editor's Rating
US $3,600.00
US $3,600.00
US $1,800.00

  • Report Details

    Summary
    Duchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 year

    More...
  • Table Of Content

    Table of Content
    1 Industry Overview
    1.1 Duchenne Muscular Dystrophy Industry
    1.1.1 Overview
    1.1.2 Products of Major Companies
    1.2 Market Segment
    1.2.1 Industry Chain
    1.2.2 Consumer Distribution
    1.3 Price & Cost Overview
    2 Duchenne Muscular Dystrophy Market by Type
    2.1 By Type
    2.1.1 Deflazacort
    2.1.2 Prednisone
    2.1.3 Others
    2

    More...
  • Inquiry Before Buying
    Inquiry Before Buying -
  • Request Sample
    Request For Sample